← Eichor
Study identifier: NCT04751409 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Stage II-III Soft Tissue Sarcoma of the Trunk and Extremities

Condition: Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 · Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8  ·  Sponsor: M.D. Anderson Cancer Center

PhasePhase 2
Planned participants227
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This phase II trial studies how anxiety is affected by 2 types of follow-up after surgery, limited follow-up and intense follow-up, in patients with stage II-III soft tissue sarcoma of the trunk and extremities. In cancer survivors, the fear of cancer coming back (recurring) is common and may persist long after the end of treatment. It may also be exacerbated by return visits for imaging (surveillance). The purpose of this study is to determine how patients' anxiety and other cancer-related outcomes are affected by how often surveillance is done.

This description comes directly from the study's public registry record.

Talk to the study team

Christina L Roland, MD  ·  713-792-6940  ·  clroland@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

M D Anderson Cancer CenterHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04751409